BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38382853)

  • 1. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
    Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
    Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy.
    Yamaguchi S; Oda S; Kidoh M; Hayashi H; Takashio S; Usuku H; Nagayama Y; Nakaura T; Tsujita K; Hirai T; Aoki T
    Acad Radiol; 2024 Feb; 31(2):514-522. PubMed ID: 37775448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping.
    Ioannou A; Patel RK; Martinez-Naharro A; Razvi Y; Porcari A; Rauf MU; Bolhuis RE; Fernando-Sayers J; Virsinskaite R; Bandera F; Kotecha T; Venneri L; Knight D; Manisty C; Moon J; Lachmann H; Whelan C; Kellman P; Hawkins PN; Gillmore JD; Wechalekar A; Fontana M
    JAMA Cardiol; 2023 Sep; 8(9):848-852. PubMed ID: 37466990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis.
    Lin L; Li X; Feng J; Shen KN; Tian Z; Sun J; Mao YY; Cao J; Jin ZY; Li J; Selvanayagam JB; Wang YN
    J Cardiovasc Magn Reson; 2018 Jan; 20(1):2. PubMed ID: 29298704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and Prognostic Value of Non-late Gadolinium Enhancement Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis.
    Briasoulis A; Lama N; Rempakos A; Theodorakakou F; Stamatelopoulos K; Dimopoulos MA; Kelekis N; Kastritis E
    Curr Probl Cardiol; 2023 Apr; 48(4):101573. PubMed ID: 36586704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.
    Barison A; Aquaro GD; Pugliese NR; Cappelli F; Chiappino S; Vergaro G; Mirizzi G; Todiere G; Passino C; Masci PG; Perfetto F; Emdin M
    J Intern Med; 2015 May; 277(5):605-14. PubMed ID: 25346163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T1 mapping and survival in systemic light-chain amyloidosis.
    Banypersad SM; Fontana M; Maestrini V; Sado DM; Captur G; Petrie A; Piechnik SK; Whelan CJ; Herrey AS; Gillmore JD; Lachmann HJ; Wechalekar AD; Hawkins PN; Moon JC
    Eur Heart J; 2015 Jan; 36(4):244-51. PubMed ID: 25411195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of T2 Mapping in Cardiac Amyloidosis.
    Grazzini G; Pradella S; Bani R; Fornaciari C; Cappelli F; Perfetto F; Cozzi D; Giovannelli S; Sica G; Miele V
    Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis.
    Chamling B; Bietenbeck M; Drakos S; Korthals D; Vehof V; Stalling P; Meier C; Yilmaz A
    Sci Rep; 2022 Dec; 12(1):21755. PubMed ID: 36526658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis.
    Ridouani F; Damy T; Tacher V; Derbel H; Legou F; Sifaoui I; Audureau E; Bodez D; Rahmouni A; Deux JF
    J Cardiovasc Magn Reson; 2018 Aug; 20(1):58. PubMed ID: 30115079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular magnetic resonance characterization of myocardial tissue injury in a miniature swine model of cancer therapy-related cardiovascular toxicity.
    Nakata K; Kucukseymen S; Cai X; Yankama T; Rodriguez J; Sai E; Pierce P; Ngo L; Nakamori S; Tung N; Manning WJ; Nezafat R
    J Cardiovasc Magn Reson; 2024 Summer; 26(1):101033. PubMed ID: 38460840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reference Ranges, Diagnostic and Prognostic Utility of Native T1 Mapping and Extracellular Volume for Cardiac Amyloidosis: A Meta-Analysis.
    Wang TKM; Brizneda MV; Kwon DH; Popovic ZB; Flamm SD; Hanna M; Griffin BP; Xu B
    J Magn Reson Imaging; 2021 May; 53(5):1458-1468. PubMed ID: 33274809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric cardiovascular magnetic resonance characteristics and dynamic changes in myocardial and skeletal muscles in idiopathic inflammatory cardiomyopathy.
    Xu Y; Sun J; Wan K; Yu L; Wang J; Li W; Yang F; Sun J; Cheng W; Mui D; Zhang Q; Xie Q; Chen Y
    J Cardiovasc Magn Reson; 2020 Apr; 22(1):22. PubMed ID: 32272936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
    Rettl R; Mann C; Duca F; Dachs TM; Binder C; Ligios LC; Schrutka L; Dalos D; Koschutnik M; Donà C; Kammerlander A; Beitzke D; Loewe C; Charwat-Resl S; Hengstenberg C; Kastner J; Eslam RB; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2022 Jun; 23(6):767-780. PubMed ID: 34788394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.
    Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H
    Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis.
    Liu Y; Zhu J; Chen M; Wang L; Zhu M; Weng Z; Hu C
    Ann Transl Med; 2022 Jul; 10(14):794. PubMed ID: 35965812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis.
    Pan JA; Kerwin MJ; Salerno M
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1299-1310. PubMed ID: 32498919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study.
    Wan K; Li W; Sun J; Xu Y; Wang J; Liu H; Dong Y; Cheng W; Zhang Q; Zeng Z; Zhou X; Han Y; Chen Y
    Amyloid; 2019 Mar; 26(1):45-51. PubMed ID: 30931628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.